New evidence suggests lowering LDL-C to 44 mg/dL with PCSK9 therapy may better protect high-risk patients with diabetes, aligning primary prevention targets with secondary prevention.
Nicholas Marston, MD, MPH
Advertisement
Nicholas Marston, MD, MPH, is a cardiologist and an assistant professor of medicine at Brigham and Women's Hospital, in Boston, MA.
Articles by Nicholas Marston, MD, MPH
ACC 2026: A new secondary analysis of the VESALIUS-CV study shows evolocumab cuts heart attacks, strokes and deaths in high‑risk patients with type 2 diabetes.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Patient Care Online
1
FDA Issues Complete Response Letter for Cingulate ADHD Drug CTx-1301
2
FDA Approves Xocova as First Oral COVID-19 Postexposure Prophylaxis Option
3
Pediatric Influenza Vaccination Linked to Fewer Diagnoses in Claims Study
4
Transdermal Hormone Therapy for VMS and Cardiovascular Risk Management
5